Table 3.
Risk Factors 1 | Events/Patients (%) | |
---|---|---|
40 mg Afatinib | 50 mg Afatinib | |
0 | 5/90 (6%) | 9/119 (8%) |
1 | 17/238 (7%) | 51/312 (16%) |
2 | 23/152 (15%) | 64/198 (32%) |
3 | 6/18 (33%) | 9/21 (43%) |
1 Female sex, age ≥60 years, and body weight <45 kg.
Risk Factors 1 | Events/Patients (%) | |
---|---|---|
40 mg Afatinib | 50 mg Afatinib | |
0 | 5/90 (6%) | 9/119 (8%) |
1 | 17/238 (7%) | 51/312 (16%) |
2 | 23/152 (15%) | 64/198 (32%) |
3 | 6/18 (33%) | 9/21 (43%) |
1 Female sex, age ≥60 years, and body weight <45 kg.